Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Julie Goodfriend"'
1
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Autor: Neil Bailey, Erica B. Bhavsar, Danielle M. Brander, Ryan Jacobs, Amber C. King, Satyen H. Gohil, Chadi Nabhan, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Pratik Shah, Bruce D. Cheson, Catherine C. Coombs, Hanna Weissbrot, Jacqueline C. Barrientos, John M. Pagel, Michael Y. Choi, Thomas D. Rodgers, Andrea Sitlinger, Rachael Pocock, Nicolas Martinez-Calle, Craig A. Portell, Lindsey E. Roeker, Andrew D. Zelenetz, Allison M. Winter, Colleen Dorsey, Javier Pinilla-Ibarz, Paul M. Barr, Othman S. Akhtar, Kate J Whitaker, Guilherme Fleury Perini, Jason C. Lee, Christine A. Garcia, Jeffrey J. Pu, Pallawi Torka, Timothy J Voorhees, Bita Fakhri, Mazyar Shadman, Ariel F Grajales-Cruz, Toby A. Eyre, Julie Goodfriend, John N. Allan, Joanna Rhodes, Kayla Bigelow, Helen Parry, Nicole Lamanna, Anthony R. Mato, Krista Isaac, Sirin Khajavian, Christopher P. Fox, Stephen J. Schuster, Kentson Lam, Talha Munir, Brian T. Hill, Alan P Skarbnik
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 14
Purpose: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. Experimental D
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b4ec23eccb2df4bc0876922b8d9c701
https://pubmed.ncbi.nlm.nih.gov/32366672
Zobrazit plný text záznamu
4
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
Autor: Mayur Narkhede, Joseph R. Carver, Maryam Sarraf Yazdy, Joanna M Rhodes, Julie Goodfriend, Anthony R. Mato, Lindsey E. Roeker
Publikováno v: JAMA Network Open
This cohort study describes patterns of development, management strategies, and long-term vascular consequences of hypertension associated with ibrutinib in the non–clinical trial setting.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45fdc136ca43fad9f562e3a2f488e0f4
https://doi.org/10.1001/jamanetworkopen.2019.16326
Zobrazit plný text záznamu
5
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Autor: Amber C. King, Michael Y. Choi, Guilherme Fleury Perini, Sirin Khajavian, Mazyar Shadman, Kentson Lam, Jason C. Lee, Bita Fakhri, Jeffrey J. Pu, Danielle M. Brander, Pratik Shah, Colleen Dorsey, Bruce D. Cheson, Kayla Bigelow, Talha Munir, Neil Bailey, Ryan Jacobs, Stephen J. Schuster, Thomas D. Rodgers, Hanna Weissbrot, Satyen H. Gohil, Lindsey E. Roeker, Andrew D. Zelenetz, Andrea Sitlinger, Pallawi Torka, Kate J Whitaker, Chaitra S. Ujjani, Nicolas Martinez-Calle, Christopher P. Fox, Brian T. Hill, Alan P Skarbnik, Paul M. Barr, Chadi Nabhan, Javier Pinilla Ibarz, Anthony R. Mato, Krista Isaac, Christine A. Garcia, Ariel F Grajales-Cruz, Allison M. Winter, Maryam Sarraf Yazdy, Toby A. Eyre, John M. Pagel, Jacqueline C. Barrientos, John N. Allan, Erica B. Bhavsar, Othman S. Akhtar, Julie Goodfriend, Helen Parry, Nicole Lamanna, Craig A. Portell, Timothy J Voorhees, Catherine C. Coombs, Rachael Pocock, Joanna Rhodes
Publikováno v: Blood. 134:502-502
Introduction: Venetoclax (VEN) based therapy has become a standard of care in front line and relapsed-refractory (R/R) CLL based on favorable efficacy and toxicity. Whereas prospective data regarding activity of therapies following ibrutinib (IBR) or
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::931e807f711f64fe625d8835d32c0fa4
https://doi.org/10.1182/blood-2019-123747
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje